Ipca Laboratories (IPCALAB) Q1 25/26 earnings summary

Executive summary

• Standalone net total income rose 12% year-over-year to ₹1,771.92 crore for Q1 FY26; consolidated net total income increased 11% to ₹2,341.51 crore.

• Standalone net profit grew 28% year-over-year to ₹262.04 crore; consolidated net profit up 18% to ₹234.42 crore.

• Domestic business grew by 10% in Q1 FY26, maintaining 16th rank as per IQVIA, with a 7 bps market share increase year-over-year.

• Branded formulations export business grew 10% to INR 124 crore, and generic formulations export business grew 15% to INR 326 crore.

• API business delivered 12% growth, with strong performance in Europe and Latin America offsetting domestic decline.

Financial highlights

• Standalone EBITDA margin improved to 23.82% from 22.25% year-over-year; consolidated EBITDA margin was 18.39% versus 18.52%.

• Standalone gross margins reached 74%, driven by favorable product mix and higher-margin therapies.

• Standalone earnings per share (EPS) rose to ₹10.33 from ₹8.05; consolidated EPS increased to ₹9.19 from ₹7.58 year-over-year.

• Standalone revenue from operations reached ₹1,746.90 crore, up from ₹1,565.86 crore; consolidated revenue from operations was ₹2,308.85 crore, up from ₹2,092.63 crore.

• Standalone finance cost decreased 38% year-over-year; consolidated finance cost fell 23%.

Outlook and guidance

• Full-year top-line growth guidance maintained at 9%-10%.

• Consolidated EBITDA margin guidance revised to a 75 bps increase (from 100 bps earlier) due to lower Unichem margins.

• Unichem not expected to achieve INR 300 crore EBITDA this year; improvement anticipated in subsequent quarters.

• Management highlighted continued growth in both domestic and export markets, with a focus on expanding branded and generic formulations.